Brepocitinib, tested in two Phase 3 CLARITY trials for non-infectious uveitis (NIU), significantly outperformed placebo on all primary and key secondary endpoints, including longer time to treatment failure and steroid-free disease control. The drug demonstrated a median time to treatment failure over 48 weeks versus about 12 weeks for placebo, and 62% of patients achieved steroid-free quiescence at 48 weeks compared to 20% on placebo. Brepocitinib also showed notable improvements in macular edema resolution and visual functioning, with a safety profile consistent with prior trials. Priovant plans to file for regulatory approval in the first half of 2027, potentially offering the first effective systemic, non-steroid treatment for NIU, a leading cause of blindness in working-age adults.
Roivant Sciences Ltd. shares are trading at USD 36.91 on Pluang as of Oct 21, 2026 18:11 WIB, up 5.70% for the day. This price is closer to the 52-week high of USD 41.81 than the low of USD 17.87, indicating strong market interest possibly linked to the positive Phase 3 trial results for brepocitinib. The stock's market cap stands at $25.23 billion, reflecting significant investor confidence in the company's health sector innovations.
Roivant Sciences announced it will report its financial results for the second quarter ending September 30, 2026, on November 9, 2026, via a live conference call and webcast. The company will also hold an investor day on December 9, 2026, providing u...
Immunovant, a clinical-stage immunology company, will announce its financial results for the second fiscal quarter ending September 30, 2026, on November 9 before the market opens. Roivant Sciences, its majority stockholder, will host a live conferen...
